ArticleBritish journal of haematology2026
Plasma calprotectin to assess susceptibility to bloodstream infections during paediatric acute lymphoblastic leukaemia induction treatment.
Article in British journal of haematology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
Abstract
Chemotherapy-induced neutropenia, monitored by peripheral blood absolute neutrophil count (ANC), increases the risk of bloodstream infections (BSIs). However, ANC may not reflect the total neutrophil population, as it omits neutrophils at extravascular sites. We therefore evaluated plasma calprotectin, a neutrophil-derived protein, as a complementary marker of neutropenia severity and BSI risk. In 114 children with acute lymphoblastic leukaemia (ALL) treated according to the NOPHO ALL2008 protocol, plasma calprotectin was measured weekly during the 4-week anthracycline-based induction therapy. Daily ANC and BSI events were obtained from medical records. All patients developed profound neutropenia (ANC <0.5 × 10
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.